Healthcare / Medical Care FacilitiesSES
$0.06
-0.00 (-1.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $53.0M · quality 55.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
N/A
•EV/EBITDA
42.5x
↑ROE
-10.1%
↓Gross Margin
74.8%
↑Debt/Equity
2.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.8%
FCF CAGR
-19.5%
FCF margin
8.6%
FCF / Net income
-0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $394.7M · net income $-47.6M · FCF $33.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $394.7M | $394.7M | $351.2M | $355.8M | $333.7M |
| Net Income | $-47.6M | $-47.6M | $14.2M | $36.6M | $53.8M |
| EBITDA | $57.7M | $57.7M | $109.1M | $106.8M | $110.7M |
| EPS | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Gross Margin | 74.8% | 74.8% | 78.4% | 83.3% | 83.4% |
| Operating Margin | -9.8% | -9.8% | 13.5% | 23.0% | 27.5% |
| Net Margin | -12.1% | -12.1% | 4.0% | 10.3% | 16.1% |
| Balance Sheet | |||||
| Debt/Equity | 2.38 | 2.38 | 2.24 | 1.53 | 1.21 |
| Current Ratio | 2.37 | 2.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $33.8M | $33.8M | $53.0M | $75.8M | $64.7M |
| Returns | |||||
| ROE | -10.1% | -10.1% | 2.8% | 7.3% | 10.1% |
| Valuation | |||||
| P/E | — | — | 92.59 | 43.48 | 38.42 |
| EV/EBITDA | 42.49 | 42.49 | 20.87 | 19.32 | 22.97 |
| P/B | 3.09 | 3.09 | 2.65 | 3.18 | 3.88 |
| Growth & Yield | |||||
| Revenue Growth | 12.4% | 12.4% | -1.3% | 6.6% | — |
| EPS Growth | -433.3% | -433.3% | -60.9% | -32.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+31.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.00 → -0.00
Residual
+31.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.